Polysaccharide fraction of Agaricus brasiliensis avoids tumor-induced IL-10 production and changes the microenvironment of subcutaneous Ehrlich adenocarcinoma

Cellular Immunology

Volumn 256, Issue 1-2, 2009, Pages 27-38

  Pinto, Andréa Vanessa Ferreira da Silva ^a   Martins, Priscila Raquel ^a   Romagnoli, Graziela Gorete ^a   Campanelli, Ana Paula ^b   Terezan, Ana Paula ^c   Filho, Edson Rodrigues ^c   Eira, Augusto Ferreira da ^a   Kaneno, Ramon ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

Author keywords

Glucan; Agaricus blazei; Angiogenesis; Ehrlich tumor; IL 10; Mushroom

Indexed keywords

AGARICUS BRASILIENSIS EXTRACT; BETA GLUCAN; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; MESSENGER RNA; PLANT EXTRACT; POLYSACCHARIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EHRLICH ASCITES TUMOR; ENZYME LINKED IMMUNOSPOT ASSAY; GIANT CELL; HISTOPATHOLOGY; IMMUNOCOMPETENCE; LYMPHOCYTE; MALE; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AGARICUS; ANGIOGENIC PROTEINS; ANIMALS; CARCINOMA, EHRLICH TUMOR; CYTOKINES; INTERFERON-GAMMA; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; POLYSACCHARIDES; RNA, MESSENGER; RNA, NEOPLASM;

AGARICUS BLAZEI; AGARICUS BRASILIENSIS; ANIMALIA; BASIDIOMYCOTA; MUS;

EID: 61849143821     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.01.002     Document Type: Article

References (40)

1. Ito H., Shimura K., Itoh H., and Kawade M. Antitumor effects of a new polysaccharide-protein complex (ATOM) prepared from Agaricus blazei (IWADE Strain 101) "Himematsutake" and its mechanism in tumor-bearing mice. Anticancer Res. 17 (1997) 277-284
2. Kawagishi H., Kanao T., Inagaki R., Mizuno T., Shimura K., Ito H., Nagiwara T., and Nakamura T. Formolysis of a potent antitumor a (1 → 6)-β-d-glucan-protein complex from Agaricus blazei Murill fruiting bodies and antitumor activity of resulting products. Carbohydr. Polym. 12 (1990) 393-403
3. Kawagishi H., Inagaki R., Kanao T., and Mizuno T. Fractionation and antitumor activity of water-insoluble residue of Agaricus blazei fruiting bodies. Carbohydr. Res. 186 (1999) 267-273
4. Wasser S.P., and Weis A.L. Therapeutic effects of substances occurring in higher basidiomycetes mushrooms: a modern perspective. Crit. Rev. Immunol. 19 (1999) 65-96
5. Kidd P.M. The use of mushroom glucans and proteoglycans in cancer treatment. Altern. Med. Rev. 5 (2000) 4-27
6. Borchers A.T., Keen C.L., and Gershwin M.E. Mushrooms, tumors, and immunity: an update. Exp. Biol. Med. 229 (2004) 393-406
7. Zaidman B.-Z., Yassin M., Mahajna J., and Wasser S.P. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl. Microbiol. Biotechnol. 67 (2005) 453-468
8. Wasser S.P., Didukh M.Y., Amazonas M.A.L.A., Nevo E., Stametsm P., and Eira A.F. Is a widely cultivated culinary-medicinal Royal Sun Agaricus (the himematsutake mushroom) indeed Agaricus blazei Murril?. Int. J. Med. Mushr. 4 (2002) 267-290
9. Fujimiya Y., Suzuki Y., Katakura R., and Ebina T. Tumor-specific cytocidal and immunopotentiating effects of relatively low molecular weight products derived from the basidiomycete, Agaricus blazei Murill. Anticancer Res. 19 (1999) 113-118
10. Kaneno R., Fontanari L.M., Santos S.A., Di Stasi L.C., Rodrigues Filho E., and Eira A.F. Effects of extracts from Brazilian sun-mushroom (Agaricus blazei) on the NK activity and lymphoproliferative responsiveness of Ehrlich tumor-bearing mice. Food Chem. Toxicol. 42 (2004) 909-916
11. Ebina T., and Fujimiya Y. Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice. Biotherapy 1 (1998) 259-265
12. Fujimiya Y., Suzuki Y., Oshiman K., Kozori H., Moriguchi K., Nakashima H., Matumoto Y., Takahara S., Ebina T., and Katakura R. Selective tumoricidal effect of soluble proteoglycan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis. Cancer Immunol. Immunother. 46 (1998) 147-159
13. Oshiman K., Fujimiya Y., Ebina T., Suzuki I., and Noji M. Orally administered β-1,6-d-polyglucose extracted from Agaricus blazei results in tumor regression in tumor-bearing mice. Planta Med. 68 (2002) 610-614
14. Romagnani S. Role of TH1 and TH2 cells against tumours. The TH1/TH2 Paradigm in Disease (1996), Springer, Berlin 159-160
15. Mocelin S., Wang E., and Marincola F.M. Review: cytokines and immune response in the tumor microenvironment. J. Immunother. 24 (2004) 392-407
16. Parmiani G., Colombo M.P., and Melani C. Immunotherapy, gene therapy, cytokines and cancer. In: Theze J. (Ed). The Cytokine Network and Immune Functions (1999), Oxford University Press, New York 346-361
17. Seung L.P., Rowley D.A., and Schreider H. Cytokines in cancer. In: Theze J. (Ed). The Cytokine Network and Immune Functions (1999), Oxford University Press, New York 335-345
18. Leek R.D., Landers R.J., Harris A.L., and Lewis C.E. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 79 (1999) 991-995
19. Elexpuru A., Martin-Nieto J., Jimenez A., Gómez C., and Villalobo A. Ehrlich ascites tumor cells produce a transforming growth factor-beta (TGF beta)-like activity but lack receptors with TGF beta-binding capacity. Moll. Cell. Biochem. 170 (1997) 871-874
20. Paiva D.L., Lampman G.M., and Kriz G.S. Introduction to Spectroscopy (1996), W.B. Saunders, Philadelphia
21. Farmacopéia Brasileira, 3rd ed., Andrei, São Paulo, 1997.
22. Ohno N., Furukawa M., Miura N.N., Adachi Y., Motoi M., and Yadomae T. Antitumor β-glucan the cultured fruit body of Agaricus blazei. Biol. Pharm. Bull. 4 (2001) 820-828
23. Takimoto H., Wakita D., Kawaguchi K., and Kumazawa Y. Potentiation of cytotoxic activity in naïve and tumor-bearing mice by oral administration of hot-water extracts from Agaricus blazei fruiting bodies. Biol. Pharm. Bull. 27 (2004) 404-406
24. Kuo Y., Huang Y., Chen C., Lin Y., Chuang K., and Tsai W. Cell cycle progression and cytokine gene expression of human peripheral blood mononuclear cells modulated by Agaricus blazei. J. Lab. Clin. Med. 140 (2002) 176-187
25. Segura J.A., Barbero L.G., and Márquez J. Early tumor effect on splenic Th lymphocytes in mice. FEBS Lett. 414 (1997) 1-6
26. Da Silva R.J., Da Silva M.G., Vilela L.C., and Fecchio D. Cytokine profile of Ehrlich ascites tumor treated with Bothrops jararaca venom. Mediators Inflamm. 11 (2002) 197-201
27. Gor D.O., Rose N.R., and Greespan N.S. TH1-TH2: a procrustean paradigm. Nat. Immunol. 4 (2003) 503-505
28. Rikha M., Corringham R., Klein B., and Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 9 (2003) 4653-4665
29. Ellyard J.I., Simson L., and Parish C.R. Th2-mediated anti-tumor immunity: friend or foe?. Tissue Antigens 70 (2007) 1-11
30. Lee I.Y., Kim J., Ko E.-M., Jeoung E.J., Kwon Y.-G., and Choe J. Interleukin-4 inibits the vascular endothelial growth factor- and basic fibroblast growth factor-induced angiogenesis in vitro. Mol. Cells 14 (2002) 115-121
31. Saleh M., Davis I.D., and Wilkis A.F. The paracrine role of tumor-derived mIL-4 on tumor-associated endothelium. Int. J. Cancer 72 (1997) 664-672
32. Volpert O.V., Fong T., Koch A.E., Peterson J.D., Waltenbangh C., Temper R.I., and Bouch N.P. Inhibition of angiogenesis by interleukin 4. J. Exp. Med. 188 (1998) 1039-1046
33. Martins P.R., Gameiro M.C., Castoldi L., Romagnoli G.G., Lopes F.C., Pinto A.V., Loyola W., and Kaneno R. Polysaccharide-rich fraction of Agaricus brasiliensis enhances the candidacidal activity of murine macrophages. Mem. Inst. Oswaldo Cruz. 103 (2008) 244-250
34. Tsuruma T., Atsuhito Y., Koichi H., Torigoe T., Araya J., Watanabe N., and Sato N. Interleukin-10 natural killer (NK) sensitivity of tumor cells by downregulating NK target structure expression. Cell. Immunol. 98 (1999) 103-110
35. Valadares M.C., Klein S.I., Guaraldo A.M., and Queiroz L.M.S. Enhancement of natural killer cell function by titanocenes in mice bearing Ehrlich ascites tumor. Eur. J. Pharmacol. 25 (2004) 191-196
36. Agarwal A., Verma S., Burra U., Murthy N.S., Mohanty N.K., and Saxena S. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol. Immunother. 55 (2006) 734-743
37. Kanazawa M., Yoshihara K., Abe H., Iwadate M., Watanabe K., Suzuki S., Endoh Y., Takita K., Sekikawa K., Takenoshita S., Ogata T., and Ohto H. Effect of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients. Anticancer Res. 25 (2005) 443-449
38. + T-cell infiltration and high microvessel density in patients with gastric cancer. Int. J. Cancer 118 (2006) 1909-1914
39. Zhong M., Tai A., and Yamamoto I. In vitro augmentation of natural killer activity and interferon-gama production in murine spleen cells with Agaricus blazei. Biosci. Biotechnol. Biochem. 69 (2005) 2466-2469
40. Ikeda H., Old L.J., and Schreiber R.D. The roles of IFN-γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13 (2002) 95-109